Lidocaine nanoparticles alleviate postoperative pain in young mice undergoing cardiovascular closure surgery by inhibiting inflammatory response

Abstract

One method for treating ventricular septal defect is cardiovascular interventional closure, but the operation is likely to cause inflammation and pain. The inflammatory response is related to inflammatory factors such as interleukin 6 (IL-6) and NF-κB and studies have found that the regulation of inflammation is related to Gq protein. Lidocaine can effectively inhibit the inflammatory response and improve pain. Nanoparticles have on-target stability. Therefore, by constructing lidocaine nanoparticles, this paper explored whether lidocaine nanoparticles could regulate the expression of Gq to mediate NF-κB, regulate the expression of inflammatory factor IL-6, and relieve postoperative pain. Lidocaine nanoparticles were constructed, prepared, and identified, and then injected into the young mice of the experimental group for modeling and grouping. Probes were used to detect the pain threshold of young mice in each group and ELISA kits were used to detect the content of IL-6 in the blood. PCR and Western blot were used to detect the relative levels of Gq, NF-κB, and IL-6. According to the pain threshold, compared with the sham operation group, lidocaine significantly reduced the pain threshold and the reduction effect of the lidocaine nano group was greater than that of the lidocaine aqueous solution group. Lidocaine nanoparticles can inhibit the expression of Gq protein and the reduced Gq expression can inhibit the expression of NF-κB and IL-6. Lidocaine nano group can directly inhibit the expression of Gq protein to inhibit NF-κB signal transduction, thereby reducing the content of IL-6 and the inflammatory response and relieving postoperative pain.